Athersys stroke treatment fails mid-stage study

April 17 (Reuters) - Drug developer Athersys Inc said its experimental cell therapy did not meet the primary and secondary endpoints of a study testing it as a treatment for a type of stroke.

Data from the mid-stage study showed that the therapy did not show a difference at 90 days compared to a placebo.

(Reporting by Vidya L Nathan in Bengaluru; Editing by Don Sebastian)

Advertisement